glp 1 patent Ozempic's problem: how Novo Nordisk lost control of a blockbuster drug. ๐ Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite China patent expiry and new
Description
GLP-1 drugs cost up to $16,000 a year
patients in pill form, expanding access to clinically proven weight-loss and cardiovascular risk-reduction therapy with broad affordability options.
Possible benefits you might notice
Check with your health insurance or your employer health program to see if it is covered
Limited-time offer
